Biology subjects

La Carrubba, V.

Publications and source records attributed to La Carrubba, V..

4 recordsLinked to original sources

bioRxiv2025

Engineered collagen-coated scaffolds for tendon regeneration: a multifunctional drug delivery approach

Tendon injuries rank among the most common musculoskeletal disorders, with their incidence rising steadily due to increased sports participation and an aging population. Current surgical treatments often fall short of clinical expectations due to poor biocompatibility, suboptimal mechanical properties, and frequent post-surgical fibrosis. Tissue engineering, however, offers promising alternatives by using biocompatible scaffolds that mimic the native tendon structure. This study aimed to develop an advanced tendon-like bundle replicating the microarchitecture and mechanical strength of native tendons. The scaffold was constructed from aligned electrospun poly-lactic acid (PLA) microfibers and designed to function as a drug delivery system for Rolipram, an antifibrotic agent. To improve cell-scaffold interactions, the scaffolds were coated with type-I collagen, a primary component of the tendon extracellular matrix (ECM). Morphological analyses confirmed the successful fabrication of smooth, well-aligned, bead-free fibers with controlled diameters, closely resembling the natural orientation and dimensions of tendon collagen fibers. Drug release was monitored for both uncoated and collagen-coated electrospun mats, with no burst release observed. Histological analysis demonstrated effective cellular infiltration by human tenocytes, with cells distributed throughout the scaffold after 14 days in culture. These results underscore the potential of tendon-like scaffolds as a promising platform for tendon repair, setting the stage for further optimization.

bioengineering↗

bioRxiv2023

Experimental Validation of an Organ-on-Chip for Mechanical Stimulation of Cell Cultures

This paper focuses on the design, fabrication, and characterization of a platform aiming to dynamically culture cells under mechanical stimulation. The platform, made of polymethylmethacrylate (PMMA), allows real-time mechanical stimuli, providing valuable insights for living tissue models. Through mechanical testing and dynamic microfluidic tests, the chip functionality was assessed. The experimental results validation showcases the potential of the device in mimicking physiological conditions, offering a promising avenue for pharmaceutical testing advancement.

bioengineering↗

bioRxiv2020

Engineered membranes for residual cell trapping on microfluidic blood plasma separation systems. A comparison between porous and nanofibrous membranes.

Blood-based clinical diagnostics require challenging limit-of-detection for low abundance, circulating molecules in plasma. Micro-scale blood plasma separation (BPS) has achieved remarkable results in terms of plasma yield or purity, but rarely achieving both at the same time. Here, we proposed the first use of electrospun polylactic-acid (PLA) membranes as filters to remove residual cell population from continuous hydrodynamic-BPS devices. The membranes hydrophilicity was improved by adopting a wet chemistry approach via surface aminolysis as demonstrated through Fourier Transform Infrared Spectroscopy and Water Contact Angle analysis. The usability of PLA-membranes was assessed through degradation measurements at extreme pH values. Plasma purity and hemolysis were evaluated on plasma samples with residual red blood cell content (1, 3, 5% hematocrit) corresponding to output from existing hydrodynamic BPS systems. Commercially available membranes for BPS were used as benchmark. Results highlighted that the electrospun membranes are suitable for downstream residual cell removal from blood, permitting the collection of up to 2 mL of pure and low-hemolyzed plasma. Fluorometric DNA quantification revealed that electrospun membranes did not significantly affect the concentration of circulating DNA. PLA-based electrospun membranes can be combined with hydrodynamic BPS in order to achieve high volume plasma separation at over 99% plasma purity.

bioengineering↗

bioRxiv2019

Polylactic acid, a sustainable, biocompatible, transparent substrate material for Organ-On-Chip and Microfluidic applications

Organ-on-chips are miniaturised devices aiming at replacing animal models for drug discovery, toxicology and studies of complex biological phenomena. The field of Organ-On-Chip has grown exponentially, and has led to the formation of companies providing commercial Organ-On-Chip devices. Yet, it may be surprising to learn that the majority of these commercial devices are made from Polydimethylsiloxane (PDMS), a silicone elastomer that is widely used in microfluidic prototyping, but which has been proven difficult to use in industrial settings and poses a number of challenges to experimentalists, including leaching of uncured oligomers and uncontrolled adsorption of small compounds. To alleviate these problems, we propose a new substrate for organ-on-chip devices: Polylactic Acid (PLA). PLA is a material derived from renewable resources, and compatible with high volume production technologies, such as microinjection moulding. PLA can be formed into sheets and prototyped into desired devices in the research lab. In this article we uncover the suitability of Polylactic acid as a substrate material for Microfluidic cell culture and Organ-on-a-chip applications. Surface properties, biocompatibility, small molecule adsorption and optical properties of PLA are investigated and compared with PDMS and other reference polymers.\n\nSignificanceOrgan-On-Chip (OOC) technology is a powerful and emerging tool that allows the culture of cells constituting an organ and enables scientists, researchers and clinicians to conduct more physiologically relevant experiments without using expensive animal models. Since the emergence of the first OOC devices 10 years ago, the translation from research to market has happened relatively fast. To date, at least 28 companies are proposing body and tissue on-a chip devices. The material of choice in most commercial organ-on-chip platforms is an elastomer, Polydymethyloxane (PDMS), commonly used in microfluidic R&D. PDMS is however subject to poor reproducibility, and absorbs small molecule compounds unless treated. In this study we show that PLA overcomes all the drawbacks related to PDMS: PLA can be prototyped in less than 45 minutes from design to test, is transparent, not autofluorescent, and biocompatible. PLA-based microfluidic platforms have the potential to transform the OOC industry as well as to provide a sustainable alternative for future Lab-On-Chip and point-of-care devices.

bioengineering↗